JP2015512397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512397A5 JP2015512397A5 JP2015503225A JP2015503225A JP2015512397A5 JP 2015512397 A5 JP2015512397 A5 JP 2015512397A5 JP 2015503225 A JP2015503225 A JP 2015503225A JP 2015503225 A JP2015503225 A JP 2015503225A JP 2015512397 A5 JP2015512397 A5 JP 2015512397A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- use according
- influenza
- infected
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 24
- BPSMYQFMCXXNPC-MFCPCZTFSA-N eritoran Chemical compound O[C@H]1[C@H](OCCCCCCCCCC)[C@@H](NC(=O)CC(=O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O[C@@H]1CO[C@H]1[C@H](NC(=O)CCCCCCCCC\C=C/CCCCCC)[C@@H](OCC[C@@H](CCCCCCC)OC)[C@H](OP(O)(O)=O)[C@@H](COC)O1 BPSMYQFMCXXNPC-MFCPCZTFSA-N 0.000 claims description 23
- 229950007107 eritoran Drugs 0.000 claims description 23
- 206010022000 influenza Diseases 0.000 claims description 21
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- 238000007920 subcutaneous administration Methods 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 6
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 6
- 239000005557 antagonist Substances 0.000 claims description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 4
- 206010011224 Cough Diseases 0.000 claims description 4
- -1 IL-1β Proteins 0.000 claims description 4
- 102000008070 Interferon-gamma Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 108010002616 Interleukin-5 Proteins 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims description 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 4
- 206010037660 Pyrexia Diseases 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 229960003130 interferon gamma Drugs 0.000 claims description 4
- 238000001361 intraarterial administration Methods 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 4
- 230000037317 transdermal delivery Effects 0.000 claims description 4
- 208000037797 influenza A Diseases 0.000 claims description 2
- 208000037798 influenza B Diseases 0.000 claims description 2
- 208000037799 influenza C Diseases 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 41
- 102000003996 Interferon-beta Human genes 0.000 description 3
- 108090000467 Interferon-beta Proteins 0.000 description 3
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 3
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 229960001388 interferon-beta Drugs 0.000 description 3
- 238000000185 intracerebroventricular administration Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616784P | 2012-03-28 | 2012-03-28 | |
| US61/616,784 | 2012-03-28 | ||
| US201361771339P | 2013-03-01 | 2013-03-01 | |
| US61/771,339 | 2013-03-01 | ||
| PCT/US2013/028856 WO2013148072A1 (en) | 2012-03-28 | 2013-03-04 | Administration of eritoran or pharmaceutically acceptable salts thereof to treat orthomyxovirus infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017006555A Division JP2017081993A (ja) | 2012-03-28 | 2017-01-18 | オルトミクソウイルス感染を処置するためのエリトラン又は薬学的に許容されるその塩の投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512397A JP2015512397A (ja) | 2015-04-27 |
| JP2015512397A5 true JP2015512397A5 (enExample) | 2016-04-21 |
| JP6081574B2 JP6081574B2 (ja) | 2017-02-15 |
Family
ID=47844539
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503225A Expired - Fee Related JP6081574B2 (ja) | 2012-03-28 | 2013-03-04 | オルトミクソウイルス感染を処置するためのエリトラン又は薬学的に許容されるその塩の投与 |
| JP2017006555A Abandoned JP2017081993A (ja) | 2012-03-28 | 2017-01-18 | オルトミクソウイルス感染を処置するためのエリトラン又は薬学的に許容されるその塩の投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017006555A Abandoned JP2017081993A (ja) | 2012-03-28 | 2017-01-18 | オルトミクソウイルス感染を処置するためのエリトラン又は薬学的に許容されるその塩の投与 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9132141B2 (enExample) |
| EP (1) | EP2830631B1 (enExample) |
| JP (2) | JP6081574B2 (enExample) |
| KR (1) | KR20140139063A (enExample) |
| CN (1) | CN104321061B (enExample) |
| AU (1) | AU2013240456B2 (enExample) |
| BR (1) | BR112014024139A8 (enExample) |
| CA (1) | CA2868458A1 (enExample) |
| IL (2) | IL234777A (enExample) |
| MX (1) | MX358470B (enExample) |
| RU (1) | RU2636622C2 (enExample) |
| TW (1) | TWI594755B (enExample) |
| WO (1) | WO2013148072A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016090404A1 (en) * | 2014-12-08 | 2016-06-16 | The University Of Queensland | Methods and compositions for treating or preventing flavivirus infections |
| JP6778681B2 (ja) * | 2014-12-12 | 2020-11-04 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | Ｈｍｇｂ１媒介性炎症の治療 |
| WO2021207218A1 (en) * | 2020-04-06 | 2021-10-14 | Eisai R&D Management Co., Ltd. | Treatment of nidovirales infection with eritoran |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681824A (en) | 1995-06-05 | 1997-10-28 | Eisai Co., Ltd. | Substituted liposaccharides useful in the treatment and prevention of endotoxemia |
| US20030130212A1 (en) * | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
| AU2001238507C9 (en) | 2000-02-18 | 2005-07-07 | Eisai R&D Management Co., Ltd. | Micelles |
| RU2289410C2 (ru) * | 2001-04-04 | 2006-12-20 | Корикса Корпорейшн | Профилактика и лечение инфекционных и других заболеваний с помощью соединений, основанных на моно- и дисахаридах |
| US7727974B2 (en) | 2001-08-10 | 2010-06-01 | Eisai R & D Management Co., Ltd. | Methods of reducing the severity of mucositis |
| AU2004218358A1 (en) * | 2003-03-05 | 2004-09-16 | Eisai R&D Management Co., Ltd. | Compositions and methods for preventing and treating endotoxin-related diseases and conditions |
| US20060211752A1 (en) * | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| EP1879597A2 (en) * | 2005-05-13 | 2008-01-23 | Eisai Co., Ltd. | Lipid a analogs for treating oral and gastrointestinal mucositis |
| EP1895842A4 (en) * | 2005-06-17 | 2009-06-03 | Univ Rochester | METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE MEMORY BY BLOCKING INTRAHEPATIC ERASURE OF ACTIVE T CELLS |
| WO2007053455A2 (en) | 2005-10-28 | 2007-05-10 | Vaxinnate Corporation | Polypeptide ligans for toll-like receptor 4 (tlr4) |
| GB0605247D0 (en) * | 2006-03-15 | 2006-04-26 | Chiron Srl | Compositions and methods for immunisation |
| WO2007139150A1 (ja) | 2006-05-30 | 2007-12-06 | The University Of Tokushima | ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤 |
| CA2669674C (en) | 2006-11-22 | 2016-05-17 | Eisai R&D Management Co., Ltd. | Sodium salt of disaccharide compound, method for producing the same, and use of the same |
| US20110201569A1 (en) | 2009-09-16 | 2011-08-18 | Heidi Ehrentraut | Methods For Treating Myocardial Disorders |
-
2013
- 2013-03-04 BR BR112014024139A patent/BR112014024139A8/pt not_active Application Discontinuation
- 2013-03-04 TW TW102107459A patent/TWI594755B/zh not_active IP Right Cessation
- 2013-03-04 WO PCT/US2013/028856 patent/WO2013148072A1/en not_active Ceased
- 2013-03-04 AU AU2013240456A patent/AU2013240456B2/en not_active Ceased
- 2013-03-04 CA CA2868458A patent/CA2868458A1/en not_active Abandoned
- 2013-03-04 JP JP2015503225A patent/JP6081574B2/ja not_active Expired - Fee Related
- 2013-03-04 MX MX2014011520A patent/MX358470B/es active IP Right Grant
- 2013-03-04 EP EP13708644.3A patent/EP2830631B1/en not_active Not-in-force
- 2013-03-04 KR KR20147029799A patent/KR20140139063A/ko not_active Withdrawn
- 2013-03-04 CN CN201380027874.XA patent/CN104321061B/zh not_active Expired - Fee Related
- 2013-03-04 RU RU2014138880A patent/RU2636622C2/ru not_active IP Right Cessation
- 2013-03-04 US US13/783,580 patent/US9132141B2/en active Active
-
2014
- 2014-09-22 IL IL234777A patent/IL234777A/en not_active IP Right Cessation
-
2015
- 2015-07-31 US US14/815,451 patent/US20160022717A1/en not_active Abandoned
-
2017
- 2017-01-18 JP JP2017006555A patent/JP2017081993A/ja not_active Abandoned
- 2017-01-19 IL IL250201A patent/IL250201A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds | |
| CO6640268A2 (es) | Formas de decodificación oral de bendamustina y su uso terapéutico | |
| CN115836079B (zh) | 烟酰胺单核苷酸和烟酰胺核苷衍生物及其在治疗特别是由流感病毒或冠状病毒引起的病毒感染和呼吸道并发症中的用途 | |
| ES3040436T3 (en) | Pharmaceutical composition comprising pyronaridine or a salt thereof, artemisinin or a derivative thereof or a combination of both for preventing or treating a respiratory disease caused by a coronavirus | |
| WO2013044871A1 (zh) | 氯喹或氯丙嗪或其衍生物或它们的混合物在制备用于治疗和/或预防肺感染和损伤的药物中的用途 | |
| KR20180074654A (ko) | 바이러스 감염의 치료를 위한 조성물 및 방법 | |
| Li et al. | TLR4 antagonist suppresses airway remodeling in asthma by inhibiting the T-helper 2 response | |
| Khalifa et al. | Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19 | |
| NZ598465A (en) | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin | |
| JP2015512397A5 (enExample) | ||
| CA2726872C (en) | Compositions for the treatment of disorders of the upper respiratory tract and influenza syndromes | |
| WO2017171653A1 (en) | A composition comprising pic for treatment of cancer | |
| RU2014138880A (ru) | Введение эриторана или его фармацевтически приемлемых солей для лечения ортомиксовирусных инфекций | |
| CN111803635B (zh) | 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用 | |
| CN108472375A (zh) | 中重度流感的治疗方法 | |
| EP4613275A1 (en) | Pharmaceutical use of nucleoside compound | |
| CN102416167B (zh) | 干扰素α与硫酸特布他林的雾化吸入剂 | |
| WO2024120452A1 (en) | Compositions and methods for prophylaxis and treatment of covid-19 | |
| WO2021181279A1 (en) | Compositions and methods for treating covid-19 infections and/or symptoms thereof | |
| CN113952457A (zh) | 泰瑞米特或含有泰瑞米特的药物组合物在抗冠状病毒中的应用 | |
| CN102416168B (zh) | 干扰素α与氨溴索的雾化吸入剂 | |
| JP2016175866A (ja) | Ａ（Ｈ１Ｎ１）ｐｄｍ０９インフルエンザウイルス感染による気管支喘息の予防又は改善剤 | |
| CN102430112B (zh) | 干扰素α与硫酸沙丁胺醇的雾化吸入剂 | |
| CN113197887B (zh) | 5-羟甲基糠醛在制备抗病毒药物中的应用 | |
| CN120478330A (zh) | 黄芩素在制备治疗人冠状病毒229e感染肺炎药物中的用途 |